Seeking Alpha

More on Baxter Q4: Acquisition charges hurt net profit

  • Baxter (BAX) net profit -34% to $326M, hurt by expenses related to its $4B acquisition of Swedish dialysis product manufacturer Gambro, collaborations and other items.
  • Gross margin dropped to 44.7% from 50.8%
  • Sales breakdown: medical products +25% to $2.59B, including $413M from Gambro. Bioscience +5% to $1.78B, mainly boosted by solid demand for Baxter's hemophilia treatments.
  • Guidance: Q1 adjusted EPS $1.06-1.09 vs consensus of $1.14; 2014 EPS $5.05-5.25 vs $5. (PR)
  • Previous
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: